Jefferies Global Healthcare Conference
Logotype for Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company (4502) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Takeda Pharmaceutical Company Limited

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Launches and psoriasis opportunity

  • MIMRYLO and ORZEYFUL launches are performing well; resources are allocated to both, while zasocitinib has FDA priority review with a decision expected in March.

  • Zasocitinib delivered 2.5x the effect of deucravacitinib on PASI 100 in a head-to-head trial; week-16 PASI 100 was ~36% by point estimate.

  • U.S. oral psoriasis treatments represent ~10% of the market; zasocitinib has no food restriction, fast onset, durability and activity across patient types.

  • Management sees room for another effective oral option as many patients prefer trying an oral before injectable therapy.

Pipeline and growth strategy

  • Strategy is to build depth in existing franchises, including IBD assets alongside ENTYVIO; the three launches begin a new cohort of growth assets.

  • Horizon One is expected to deliver low growth as marketed products mature; savings will be reinvested in launches and pipeline, with core operating profit margins protected.

  • Horizon Two begins as the first launches scale and a second product wave launches, supporting longer-term sustainable growth.

  • ORZEYFUL targets narcolepsy type 1; TAK-360 and TAK-495 are clinical orexin-2 agonists, with another molecule planned for the clinic and next-generation orexin-1 research underway.

  • Zasocitinib psoriatic arthritis data are expected next year; UC and Crohn's phase II data are expected by fiscal year-end, with phase III preparations underway pending Crohn's results and dose decisions.

Investment and capital allocation

  • Commercial investment is nearly JPY 100bn this year and may rise next year, the first full year for the three launches; transformation savings fund launch spending.

  • Savings are expected to be fully annualized next year, alongside annualized launch spending and increased phase III investment; management cautioned that launches are not typically profit-accretive in year one.

  • Free cash flow supports growth investment, deleveraging and dividends; the progressive dividend policy targets maintaining or increasing dividends, with ~40% of FCF going to dividends.

  • Net debt/adjusted EBITDA is 2.5x; the target is 2x before U.S. ENTYVIO biosimilar entry.

  • Business development will focus on complementary assets that deepen existing therapeutic areas, especially earlier-stage pipeline; attractive late-stage opportunities remain under review.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Takeda Pharmaceutical Company